Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Just when you had written off biotech stocks as boring, here comes the MIT Technology Review to name its “Three technologies ...

A research team led by the University of Oxford's Department of Engineering Science has shown it is possible to engineer a ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the ...

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The discussion focuses on how KAIMRC integrates clinical research, biobanking, data infrastructure, and translational science ...